Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD/MAD and DDI Study of PBI-0451 in Healthy Subjects
NCT05011812Phase 1Completed
- Sponsor
- Pardes Biosciences
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pomotrelvir in coronavirus disease 2019 (COVID-19) (14 arms), sponsored by Pardes Biosciences. Primary endpoints: Treatment Emergent Adverse Events, Clinically Significant Change from Baseline in Vital Signs and 1 more. Started Aug 2021; status: completed.
02
Drugs
pomotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05011812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011812.